BailiTianheng (688506.SH): The first subject has been enrolled in the Phase III clinical trial of innovative biological drug BL-B01D1 for injection.

Baili Tianheng (688506.SH) announced that the Phase III clinical trial of the innovative biopharmaceutical injection BL-B01D1 (EGFRHER3 dual-target ADC) independently developed by the company in combination with osimertinib for first-line EGFR-mutant locally advanced or metastatic non-small cell lung cancer has recently completed the enrollment of the first subject. BL-B01D1 is a dual-target ADC drug developed independently by the company, which is the world's exclusive drug in the Phase III registration clinical trial stage targeting both EGFR and HER3 simultaneously. Recently, the clinical study of BL-B01D1 in combination with osimertinib for first-line EGFR-mutant locally advanced or metastatic non-small cell lung cancer has entered the Phase III clinical trial stage and completed the enrollment of the first subject. As of now, BL-B01D1 is undergoing approximately 30 clinical trials for various types of tumors in China and the United States. In addition to the newly enrolled clinical trial, BL-B01D1 is also in the stage of subject enrollment in seven domestic Phase III registration clinical trials for lung cancer, breast cancer, nasopharyngeal cancer, esophageal squamous cell carcinoma, and others.